Recce Pharmaceuticals Granted Japanese Patent for RECCE® Anti-Infectives
MWN-AI** Summary
Recce Pharmaceuticals Ltd, an innovator in synthetic anti-infectives, announced the granting of a Family 4 patent by the Japan Patent Office for its anti-infective compounds, RECCE® 327 (R327) and RECCE® 529 (R529), which will expire in 2041. This patent recognition emphasizes Recce's commitment to tackling significant unmet medical needs in infectious disease treatment. CEO James Graham expressed optimism regarding this recognition, highlighting Recce's capability to deliver innovative therapies globally.
The Japan Patent covers various aspects, including the preparation processes for the RECCE® anti-infectives, as well as their application against a range of diseases such as bacterial and viral infections. Notably, these treatments have shown promise in managing acute bacterial skin infections, diabetic foot infections, lung infections, and more, with potential for diverse administration methods, including oral, inhalation, and transdermal.
With Japan standing as the third-largest pharmaceutical market worldwide, comprising about 5% of the global sector, the antibiotic resistance market alone is projected to reach $411.3 million by 2030. This growth represents a compound annual growth rate of 6.1% from 2024 to 2030, indicating a flourishing market for innovative anti-infectives like those developed by Recce.
Recce's portfolio includes R327, an injectable and topical therapy targeting life-threatening bacterial infections, R435 for bacterial infections in oral form, and R529 for viral infections. The World Health Organization has recognized Recce's products as essential in combating antimicrobial resistance, with the FDA designating R327 as a qualified infectious disease product, granting it Fast Track status and extended market exclusivity post-approval. This strategic positioning aims to address critical health needs through unique technological innovations in a rapidly evolving medical landscape.
MWN-AI** Analysis
Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) has made significant strides by securing a Family 4 patent for its anti-infective products in Japan, further reinforcing its position in the burgeoning pharmaceutical market. This patent covers their innovative compounds RECCE® 327 (R327) and RECCE® 529 (R529), aimed at tackling a spectrum of infections from bacterial to viral, and extends patent protection until 2041. Given that Japan is the third-largest pharmaceutical market globally, making up approximately 5% of the global share, and possessing a significant antibiotic resistance market projected to reach $411.3 million by 2030, this strategic move could bolster Recce's market presence and financial outlook.
The implications of this patent grant are manifold. It not only underscores Recce’s commitment to addressing critical unmet medical needs but also positions its anti-infective pipeline favorably against rising antibiotic resistance, a major global health challenge. The global market for antibiotics is experiencing a compound annual growth rate (CAGR) of 6.1%, indicating robust demand. Recce’s unique approach, with a pathway for diverse delivery methods including oral, inhalation, and transdermal administration, enhances market appeal by potentially reaching a broader patient demographic.
For investors, Recce Pharmaceuticals represents a compelling opportunity, particularly as their ongoing clinical trials exhibit measurable progress and recognition from health authorities like the FDA and WHO adds credibility. The company's strong patent portfolio and proprietary manufacturing capabilities further mitigate risk associated with product development.
In summary, with new patent rights in a lucrative market and a growing pipeline addressing urgent health needs, investors might consider Recce Pharmaceuticals for potential growth, especially as the landscape shifts towards novel anti-infective solutions. However, close monitoring of clinical trial outcomes and market shifts in the antibiotic landscape will remain essential.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
SYDNEY, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), (Recce or the Company) the Company developing a new class of synthetic anti-infectives, today announced it was granted a Family 4 patent by the Japan Patent Office for its anti-infectives, with expiry in 2041.
“We are encouraged by the Japan Patent Office’s formal recognition of Recce’s new class of anti-infectives,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals. “Global patent protection underscores our commitment to addressing critical unmet medical needs with innovative therapies. We are well-positioned to deliver meaningful solutions for patients worldwide.”
The Japan Patent claims relate to RECCE ® 327 (R327) and RECCE ® 529 (R529), including:
- Process for preparation of RECCE ® anti-infectives
- Use of R327/R529 for the treatment of disease, particularly the treatment of bacterial infections, viral infections, and more
- Specifically, further validating RECCE ® anti-infectives from studies in acute bacterial skin and skin structure infections (ABSSSI), diabetic foot infections (DFI), burn wounds, lung infections (i.e., ventilator-associated pneumonia/hospital-acquired pneumonia), urinary tract infections, gonorrhoea, influenza, and SARS-CoV2
- Administration by oral, inhalation, transdermal delivery, or by injection (into the bloodstream, intramuscular, and/or intravenous)
- Administration may also be applied as an aerosol, gel, topical foam or ointment (or impregnated into a dressing for application to skin or mucous membranes for transdermal or transmucosal delivery)
This is the fourth Family 4 patent, alongside Australia, Canada, and Israel, with further Patent Cooperation Treaty Country (PCT) submissions in respective stages of review/allowed.
Japan is the third largest pharmaceutical market in the world, 1 with a share of approximately 5% of the global pharmaceutical market. 2 The antibiotic resistance market in Japan is expected to reach a projected revenue of $411.3 million by 2030. The Japanese antibiotic resistance market expects a compound annual growth rate of 6.1% from 2024 to 2030. 3
About Recce Pharmaceuticals Ltd
Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is developing a New Class of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic-resistant superbugs.
Recce’s anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE ® 327 (R327) as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria, including their superbug forms; RECCE ® 435 (R435) as an orally administered therapy for bacterial infections; and RECCE ® 529 (R529) for viral infections. Through their multi-layered mechanisms of action, Recce’s anti-infectives have the potential to overcome the processes utilised by bacteria and viruses to overcome resistance – a current challenge facing existing antibiotics.
The World Health Organization (WHO) added R327, R435, and R529 to its list of antibacterial products in clinical development for priority pathogens, recognising Recce’s efforts to combat antimicrobial resistance. The FDA granted R327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act, providing Fast Track Designation and 10 years of market exclusivity post approval. R327 is also included on The Pew Charitable Trusts’ Global New Antibiotics in Development Pipeline as the sole synthetic polymer and sepsis drug candidate in development.
Recce wholly owns its automated manufacturing, supporting current clinical trials. Recce’s anti-infective pipeline aims to address synergistic, unmet medical needs by leveraging its unique technologies.
Corporate Contact
James Graham
Recce Pharmaceuticals Ltd
+61 (02) 9256 2571
James.graham@recce.com.au
Media & Investor Relations (AU)
Andrew Geddes
CityPR
+61 (02) 9267 4511
ageddes@citypublicrelations.com.au
Media (USA)
Michael Fitzhugh
LifeSci Communications
mfitzhugh@lifescicomms.com
Investor Relations (USA & EU)
Guillaume van Renterghem
LifeSci Advisors
gvanrenterghem@lifesciadvisors.com
1 https://www.trade.gov/country-commercial-guides/japan-pharmaceuticals
2 https://www.statista.com/statistics/275535/distribution-of-global-pharmaceutical-market-revenue/
3 https://www.grandviewresearch.com/horizon/outlook/antibiotic-resistance-market/japan
FAQ**
How does Recce Pharmaceuticals Ltd (ASX: RCE) plan to leverage its newly granted Family 4 patent in Japan to enhance its market position in the antibiotic resistance sector, particularly with its products RECCE 327 and RECCE 529, and what role will Recce Pharmaceuticals Ltd RECEF play in this strategy?
With the Japanese antibiotic resistance market projected to reach $411.3 million by 2030, how does Recce Pharmaceuticals Ltd (ASX: RCE) intend to compete effectively against existing treatments, and will Recce Pharmaceuticals Ltd RECEF be involved in this competitive landscape?
What are the anticipated milestones for Recce Pharmaceuticals Ltd (ASX: RCE) in the upcoming years regarding clinical trials for R327 and R529, and how will these developments impact the company’s growth trajectory, particularly for stakeholders in Recce Pharmaceuticals Ltd RECEF?
Given the focus on antibiotic-resistant superbugs, how does Recce Pharmaceuticals Ltd (ASX: RCE) plan to utilize its automated manufacturing for clinical trials, and what implications does this have for investors, specifically those considering Recce Pharmaceuticals Ltd RECEF?
**MWN-AI FAQ is based on asking OpenAI questions about Recce Pharmaceuticals Ltd (OTC: RECEF).
NASDAQ: RECEF
RECEF Trading
0.0% G/L:
$0.22 Last:
5,000 Volume:
$0.22 Open:
